What are your practical considerations for incorporating bispecific antibody therapy into treatment of relapsed DLBCL?

In relapsed/refractory DLBCL, if the patient has not yet received bispecific antibody (BsAb) and/or CAR T-cells, and the patient is eligible and able to receive CAR T-cells, I favor CAR T-cells before BsAb, given extensive follow-up time demonstrating CAR T-cells are a potentially curative approach ...

CD20xCD3 bispecific antibodies are a very promising class of drugs available for relapsed DLBCL, with response rates ~50-60% as monotherapy and approaching 70% in combination with chemotherapy (GemOx). Glofitamab or epcoritamab in combination with GemOx is available in the 2nd-line setting if the pa...

The practical considerations for incorporating bispecific antibodies into the treatment of relapsed DLBCL is the awareness of the potential side effects, although less than CAR T-cell therapy, in regards to the risk of cytokine release syndrome (CRS) and immune-effector cell associated neurotoxicity...

Bispecific antibodies are a very effective class of agents for lymphoma, including relapsed DLBCL. However, it is unclear whether they offer curative-intent therapy, and so I still typically sequence CAR T prior to bispecific antibodies, except in cases where patients absolutely cannot receive CAR T...